ASND vs NBTX
Ascendis Pharma A/S and Nanobiotix S.a., side by side — 8 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | ASND | NBTX |
|---|---|---|
| Revenue | €720.1M | €32.6M |
| Net income | €-228.0M | €-24.0M |
| Gross margin | 86.8% | · |
| Net margin | −31.7% | −73.5% |
| Return on equity | · | · |
| Diluted EPS | −€3.76 | −€0.50 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | · | €-34.0M |
| Equity | · | · |
| Net debt / equity | · | · |
| Current ratio | 1.04× | 1.09× |
| Revenue CAGR 5y | 153.0% | 67.0% |
| Profit CAGR 5y | · | · |
ASND bills 22.1× the revenue of NBTX, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
8 years side by side
| Fiscal year | ASND | NBTX |
|---|---|---|
| FY2025 | €720.1M | €32.6M |
| FY2024 | €363.6M | €-7.2M |
| FY2023 | €266.7M | €36.2M |
| FY2022 | €51.2M | €4.8M |
| FY2021 | €7.8M | €2.6M |
| FY2020 | €7.0M | €2.5M |
| FY2019 | €13.4M | €2.5M |
| FY2018 | €10.6M | €3.5M |
Bottom line
| Fiscal year | ASND | NBTX |
|---|---|---|
| FY2025 | €-228.0M | €-24.0M |
| FY2024 | €-378.1M | €-68.1M |
| FY2023 | €-481.4M | €-39.7M |
| FY2022 | €-583.2M | €-57.0M |
| FY2021 | €-383.6M | €-47.1M |
| FY2020 | €-419.0M | €-33.6M |
| FY2019 | €-218.0M | €-50.9M |
| FY2018 | €-130.1M | €-30.3M |
8 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +€687,539,000 | ASND |
| FY2024 | +€370,832,000 | ASND |
| FY2023 | +€230,511,000 | ASND |
| FY2022 | +€46,398,000 | ASND |
| FY2021 | +€5,131,000 | ASND |
| FY2020 | +€4,441,000 | ASND |
| FY2019 | +€10,834,000 | ASND |
| FY2018 | +€7,102,000 | ASND |
ASND has reported the higher revenue in every one of these 8 fiscal years. The gap has widened since the earliest year compared.
8 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ASND's net margin has been more volatile than NBTX's over the 4 comparable fiscal years — 542.7 percentage points of standard deviation against 484.3.
4 of 7 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ASND and NBTX over these 4 fiscal years — ASND led in 2 and NBTX in 2.
4 of 7 comparable fiscal years — a year missing data on either side is not counted.